The Cell That Learns to Die: A Historical Development Review of Apoptosis from Nematodes to Medicine

Abstract

This article offers a historical development review of apoptosis, the programmed cell death whose discovery transformed cell biology's understanding of life's regulation, and whose development from the morphologists' 1972 naming through the nematode genetics' dissection to the medicine's Bcl-2 era is the model case of a cell behavior's mechanism's career. The review reconstructs the development across five phases: the morphological discovery, John Kerr, Andrew Wyllie, and Alastair Currie's 1972 naming of apoptosis, whose the shrinkage's and the blebbing's and the fragmentation's signature the pathology distinguished from necrosis; the nematode dissection, John Sulston's and Robert Horvitz's lineage studies and Hilary Ellis's and Horvitz's ced mutants, whose the 131 cells's deaths the worms's genetics mapped to genes; the molecular conversion, Junying Yuan's and Michael Hengartner's identifications whose the ced-3's protease and the ced-9's protector the cell death's machinery revealed; the human connections, David Vaux's, Suzanne Cory's, and Jerry Adams's Bcl-2 discovery, whose the lymphoma's oncogene the death's inhibitor revealed, and Craig Thompson's disease synthesis; and the clinical era, whose the cancer therapies's and the immune biology's and the neurodegeneration's programs the apoptosis's knowledge informs. Three synthetic claims are advanced. First, apoptosis's history is the morphology's vindication, since the 1972 paper's descriptive gift supplied the concept whose the genetics's and the molecular's eras filled, and the case's lesson is that the careful phenotype's naming can launch a field. Second, the nematode's contribution displays the model organism's method at its purest, whose the transparent lineage's 959 cells the death's genetics made countable. Third, the Bcl-2 discovery's lesson, that an oncogene can be a death inhibitor, inverted the cancer paradigm's growth logic and made cell death the therapy's target, whose the clinical programs's translation the field's present pursues. An agenda is proposed spanning the death's subroutines, the clinical translation, and the regulated death's non-apoptotic families.